Insights
Beauty treatments: High fashion or high risk?
29 Jul 2025The Chartered Trading Standards Institute has released important guidance on “at home” beauty treatments, and the risks that are posed in using them. Beauty treatments such as lash lifts and manicures are becoming more and more accessible at home, with kits that appear to be great value for money being sold online. But do you know the risks you are exposing yourself to by using them?
Parallel imports into the UK: still no change to the law
28 Jul 2025In May, the government published its response to the Intellectual Property Office's (UK IPO) consultation on the UK's future exhaustion regime for intellectual property rights (IPR). The government has announced that the current UK+ exhaustion regime will continue in place.
Government Industrial Strategy targets UK in top three life sciences economies in 10 years
28 Jul 2025The Government has published its new 10-year Industrial Strategy. It was developed in collaboration with businesses and aims to make the UK the best place in the world to invest, generate growth, and create jobs across all regions. Eight growth sectors (the IS-8) are the focus, including life sciences, digital/AI, and advanced manufacturing. Others are clean energy, defence, finance, professional and business services, and creative industries.
Navigating insolvency risks: Directors’ duties for pharmaceutical industry professionals
28 Jul 2025Operating within the UK pharmaceutical sector offers immense opportunities for innovation and public health impact. However, it also presents significant financial and regulatory challenges.
Devolution in focus: Introducing the English Devolution and Community Empowerment Bill
25 Jul 2025An early overview of the English Devolution and Community Empowerment Bill, unpacking the key proposals, unexpected omissions and what they could mean for the future shape of local government in England
MHRA proposes sensible new plan for boosting medical devices in UK
25 Jul 2025Was Brexit good for the UK? It depends on your perspective. For UK life sciences businesses, the “B” word still provides strong opinions. Some people have accepted the decision even if they think it was a mistake. Others think that Brexit provided a good opportunity for the sector, but the UK could have done more to benefit from the opportunities or “Brexit freedoms”. The debate rumbles on.
